Category: Patient Rights

Kapa3 joins PERIFORMANCE: From Information to Trust in Cancer Care

Kapa3 – Cancer Guidance Centre is pleased to announce that its proposal, “From Information to Trust: MYRTO Patient & Citizen Lab for Equal Access in Cancer Care,” has been selected for funding under the PERIFORMANCE Open Call for Bottom-Up Stakeholder Engagement Initiatives in Cancer Research & Care.

The initiative places patients, caregivers, healthcare and social care professionals, civil society organisations and local communities at the heart of the process, creating a participatory framework for the ethical, trustworthy and inclusive use of AI-enabled cancer navigation.

Putting patients and citizens at the centre

The project is closely linked to MYRTO, Kapa3’s AI-enabled digital social assistant designed to support people affected by cancer in navigating health, social care, administrative procedures and rights-related information.

PERIFORMANCE funding will not support the core technical development of MYRTO. Instead, the project will focus on building the participatory, educational and ethical layer around the tool, ensuring that its future development is shaped by the real needs, experiences and expectations of the people who will use it.

This approach reflects a key principle for Kapa3: technology should not replace human care. When designed responsibly, however, it can become a powerful tool for improving access, empowerment and equality.

From local communities to a national dialogue

The engagement pathway will include regional listening activities, a thematic focus on vulnerable and underrepresented groups, and a central MYRTO Patient & Citizen Lab in Athens.

Particular attention will be given to caregivers, older patients, migrants, people with disabilities, people with low health or digital literacy, socially vulnerable groups and people living far from specialised oncology services.

The Athens Lab will be integrated into Kapa3’s national conference “Equality in Access”, creating a space for synthesising regional experiences, identifying trust criteria and collecting patient and caregiver perspectives on AI-supported navigation.

What does trust in AI-supported cancer navigation mean?

At the heart of the project lies a fundamental question:

What does a person need in order to trust a digital tool during one of the most sensitive periods of their life?

Through co-creation and stakeholder engagement, the initiative will explore issues such as:

  • reliability and clarity of information,
  • data protection and privacy,
  • accessibility and digital inclusion,
  • responsible use of Artificial Intelligence,
  • prevention of bias and exclusion,
  • human oversight,
  • and clear referral pathways to appropriate professionals when human support is needed.

Bringing together science, civil society and lived experience

Kapa3 will coordinate the initiative and lead its design, implementation, facilitation, patient and community outreach, dissemination and reporting.

The project will be supported by a multidisciplinary academic and scientific collaboration network involving the International Hellenic University – Department of Nursing, University of West Attica – Department of Occupational Therapy, Democritus University of Thrace – Department of Social Work, and University of the Peloponnese – Department of Nursing. simasiaAI will provide technical support for MYRTO-related digital materials and the AI navigation environment.

The project is expected to produce practical resources including a Patient Guidance Toolkit, a Trust & Human Escalation Checklist, a Training and Dissemination Package, and an Engagement & Trust Report.

From information to trust

For Kapa3, participation in PERIFORMANCE marks another step towards ensuring that the patient voice is present not only when new services and technologies are evaluated, but from the very beginning of their design.

With MYRTO, the question is no longer simply:

“How can we provide more information?”

It is increasingly:

“How can we turn information into understanding, trust, safety and real access?”

Because responsible digital health innovation begins with people.

The Right to Be Forgotten: A New Era of Dignity for Cancer Survivors

Life after cancer should not be accompanied by lifelong financial exclusion

For many decades, completing cancer treatment did not always mean the end of obstacles for those who had been diagnosed with the disease. Years after their treatment, many survivors continued to face higher insurance premiums, denied insurance applications, and difficulties accessing financial services.A history of cancer could act as a permanent “stigma,” even many years after treatment had ended.

Thus, medical progress and a return to daily life were not always accompanied by corresponding social and economic rehabilitation.

With Law No. 5317/2026, published on July 10, 2026, Greece is moving forward with the legislative enshrinement of the so-called “Right to Be Forgotten” for cancer survivors, in the context of insurance contracts linked to consumer credit agreements. This specific provision is found in Article 16, paragraph 4, of the law.

What the new provision stipulates

The law prohibits the use of personal data related to a consumer’s cancer diagnosis when such data is to be used for an insurance contract linked to a credit agreement and five years have passed since the completion of treatment.

Simply put, once the five-year period has elapsed, a prior history of a cancer diagnosis cannot be used in this specific context as a factor in assessing the insurance contract accompanying the credit agreement. This represents a significant shift: individuals are no longer assessed indefinitely through the lens of a past
illness, but are given the opportunity to move forward with their lives without their previous diagnosis serving as a permanent obstacle.

The four key points of the new entitlement

The Right to be Forgotten does not mean that the diagnosis is deleted from the medical record. It means that, after the prescribed five-year period, data related to the cancer diagnosis may not be used for that specific insurance purpose.

Fourth, special oversight is provided for.

The Personal Data Protection Authority is responsible for enforcing paragraph 4 of Article 16 and possesses the supervisory and auditing powers provided for by the General Data Protection Regulation.

What the New Regulation Does Not Cover

Accurate information is particularly important so that citizens are aware of both their rights and the actual
limits of the protection provided.

The new legislative provision:

  • does not apply to all forms of private insurance,
  • does not automatically guarantee the approval of a loan or an insurance application,
  • does not cover credit agreements secured by a mortgage on real property,
  • does not cover credit intended for the purchase or retention of rights in real estate,

does not cover professional or business loans, as the law applies to consumers acting outside the
scope of their professional or business activities.

Furthermore, consumer credit agreements already in effect as of November 20, 2026, will, as a general rule, continue to be governed by the previous legal framework until their expiration.
Therefore, the new regulation represents a very important step, but it does not yet provide comprehensive coverage of all the financial and insurance needs of survivors.

From Voluntary Commitment to Legal Enshrinement

The Right to Be Forgotten did not first appear in Greece in 2026. As of March 26, 2024, the Code of Ethics of the Hellenic Association of Insurance Companies has been in effect, to which life insurance companies had adhered.

The Code applied to life insurance policies linked to mortgage, business, or consumer loans, with a maximum total insured amount of 300,000 euros. It provided for a ten-year period following the completion of treatment for those diagnosed as adults and a five-year period for those diagnosed before
turning 18.

The new legislation is particularly significant because protection is no longer based exclusively on the insurance industry’s voluntary commitment. For contracts falling within its scope, the failure to use the oncological diagnosis after the five-year period becomes a legal obligation.

At the same time, there is a need to clarify the relationship between the new law and the existing Code, particularly with regard to mortgage and business loans that are not subject to the new legislative provision.

Additional Safeguards for Consumers

Article 16 includes other important safeguards. When insurance is required for the granting of credit, the creditor must accept equivalent insurance coverage from an insurance company of the consumer’s choice. Choosing a different company must not result in less favorable credit terms.

At the same time, the consumer is given a period of at least three business days to compare insurance quotes, unless the consumer requests in writing that the contract be concluded earlier.

The European Dimension

The Greek regulation transposes Directive (EU) 2023/2225 on consumer credit agreements. The European
Directive requires Member States to establish a time limit beyond which data related to oncological
diagnoses may not be used for insurance policies linked to credit agreements. The European text stipulated that this period must not exceed fifteen years; Greece opted for the significantly shorter period of five years.

This choice has particular social significance. It recognizes that advances in oncology, increased survival rates, and people’s return to family, social, and professional life must be accompanied by corresponding
developments in the law.

When Does It Take Ef ect?

Although Law No. 5317/2026 has already been published, the provisions of Part A, which include the
Right to Be Forgotten, will take effect on November 20, 2026.
Until then, substantial preparation is required on the part of banks, insurance companies, and the relevant
authorities. Clear procedures, understandable information for citizens, appropriate staff training, and an
easily accessible mechanism for submitting reports or complaints are needed.

A Significant Achievement—Not the End of the Journey

The Right to Be Forgotten represents a significant institutional victory for dignity and equality. Cancer
should not be a lifelong social and economic stigma. A person’s medical history should not negate their
right to plan for the future, participate equally in society, and make a fresh start.
At the same time, the new regulation must be viewed as a starting point, not the culmination of our
efforts. The next step must be to extend meaningful protection to more insurance and financial products,
including housing needs, as well as to address the discrimination that continues to occur in the workplace
and other aspects of social life.
Scientific progress has transformed cancer from a terminal diagnosis into an experience of life and
survival for millions of people. Society and the law must follow suit.

Because the Right to Be Forgotten is not a privilege. It is every person’s right not to remain forever
trapped by a past diagnosis—and to move forward into the future without discrimination, without
stigma, and with dignity.

Find more : http://elib.aade.gr/elib/view?

New Joint Ministerial Decision on the 2026 Aerotherapy Allowance: A Detailed Guide for KAPA3 Beneficiaries

At the Cancer Patient Guidance Center—KAPA3, we remain committed to providing accurate and timely information to cancer patients and their families regarding the rights and social benefits to which they are entitled. With the aim of making your daily life easier and ensuring you have full access to beneficial legislative provisions, we present a comprehensive guide to the granting of the air therapy allowance, in accordance with the recent Joint Ministerial Decision (No. 89399 EX 2026) published in the Government Gazette, Issue B, No. 3295, dated June 11, 2026.

The air therapy allowance applies to the summer season of 2026.

The amount is set at 250.00 euros and will be paid as a lump sum to the beneficiaries’ bank accounts on July 10, 2026.

The amount is unseizable and fully exempt from any tax or withholding.

  1. Who Are the Beneficiaries

The benefit is granted to disabled retirees of the State and the e-EFKA. Specifically, beneficiaries are those who fall into the following categories:

a) Pensioners referred to in subparagraphs (a) and (b) of paragraph 1 of Article 6 of Legislative Decree 4605/1966.

b) Pensioners under subparagraph (c) of the aforementioned paragraph 1 of Article 6 of Legislative Decree 4605/1966, who, according to 

the opinion of the competent Health Committee for the years 2020 through 2026, have been deemed to be in need of this allowance and belong to the following categories of retirees:

  1. Disabled officers under Law No. 2588/1921 and Law No. 875/1979 on military retirement.
  2. Disabled officers under Law No. 362/1943.

iii. Disabled enlisted personnel under Article 1 of Legislative Decree 1044/1971, as amended by Article 1 of 

Law 1043/1980.

Disabled members of the former Municipal Police who were subject to Legislative Decree 330/1947.

Disabled members of the Security Forces under Law 1579/1950 and those disabled members of the Coast Guard,

the Fire Department, and the Agricultural Police who are treated as equivalent to them.

Disabled members of the National Resistance under Provisional Act 1855/1951, Legislative Decree 412/1970, and Law 1543/1985.

vii. Persons with disabilities under Law 1370/1944 (who sustained their disabilities during peacetime while in service and as a result thereof, and 

receive a disability pension).

viii. Persons with disabilities from the anti-dictatorship struggle under Law 1543/1985.

Disabled civilians under Law 812/1943.

Disabled civilians under Law 1863/1989.

c) Civilian retirees who sustained disabilities as a result of their service (Decision of the Ministry of Labor and Social Security No. 

754.6/117/3912/March 24, 1969) and

d) OSE retirees who left the service and are receiving a pension due to tuberculosis.

3. Who Is Exempt from Payment

According to the Government Gazette, the following categories are not eligible for the air therapy allowance:

Recipients of other benefits: Those who have received or are set to receive a corresponding air therapy allowance from any other source (such as public entities, private entities, public benefit organizations, etc.).

Spa Therapy Beneficiaries: Those who have been deemed eligible for spa therapy for the year 2026 by the Directorate for Reserve Combatants, Veterans, War Victims, and War Disabled (DEPATHA).

New Pensioners: Citizens whose pension is payable after September 30, 2026, or whose order for registration in the Pensioner Registers is issued after October 31, 2026.

  1. What to Do in Case of Non-Payment

If you are eligible but the benefit does not appear in your account by the scheduled date of July 10, 2026, the law entitles you to file a retroactive claim.

You may submit a request by December 31, 2026, at the latest, to the following agencies (depending on your category):

To Section E of the Income Policy Directorate of the General Accounting Office (p. 2) .

To the General Directorate of Public Sector Pensions of e-EFKA (p. 2).

You can contact the Kapa3 team 

13 Kostis Palamas Street, 3rd floor (Hours: 9:00 a.m. – 5:00 p.m.).

Contact Numbers: 210 5221424 & 6906265170.

Email: info@kapa3.gr

Disability Card: Everything KAPA3 beneficiaries need to know about its use and their rights

The Cancer Patient Guidance Center (KAPA3) informs beneficiaries and their caregivers about Clarification Circular No. 12757 issued by the Ministry of Social Cohesion and Family. This circular clarifies the framework for the operation, recognition, and mandatory acceptance of the Disability Card by all relevant agencies.

The Disability Card is the official government document that verifies the holder’s identity and status as a person with a disability. The primary purpose of issuing the card is to protect sensitive personal data, as it does not contain any information regarding the nature of the condition or disability.

Below is a detailed summary of all provisions under the law:

  1. Obligations of Entities and Rights to Service

Mandatory Acceptance: The Card must be accepted by all public and private sector entities, as well as by individuals and legal entities 

Priority Service: All entities are required to give priority service to Cardholders in procedures requiring in-person presence and to provide accessibility accommodations.

  1. The Three Forms of the Card (Equal Evidential Value)

Customer service staff are required to accept the Disability Card in whichever of the following forms the citizen chooses.

Printed form: A document with a digital signature from the online portal karta.epan.gov.gr.

Digital form: Via the Gov.gr Wallet app on a mobile device.

Plastic card: A printed form with a standardized design.

  1. Disability Levels and Right to an Attendant

The Card indicates the total disability percentage across three levels, in order to grant the corresponding rights:

Level I: Disability of 50%–66%.

Level II: Disability of 67%–79%.

Level III: Disability of 80% or higher.

“S” Marking (Right to a Companion): If the Card bears the “S” marking, all benefits, rights, and accommodations provided to the cardholder automatically extend to their companion during the period of accompaniment.

  1. What is the status of existing disability certificates?

Please note that disability certificates issued by the competent health committees (KEPAs, ASYE, etc.) remain valid as usual. Citizens who present these certificates instead of the Disability Card will be served as usual in accordance with the provisions applicable to each benefit.

The KAPA3 team stands firmly by patients and caregivers to provide guidance and ensure their rights are protected. For any information or support regarding the use of the Disability Card, please contact us.

 

Mapping the efficiency of cancer care in Greece: findings from the All.Can Greece report

Cancer care efficiency in Greece remains one of the most complex and pressing challenges for the Greek health system — not only in terms of its clinical burden, but also in how care is organized around the patient.

With approximately 63,000 new cancer cases diagnosed annually and more than 32,000 cancer-related deaths each year, Greece faces a steadily increasing oncological burden. Projections suggest that cancer incidence will rise by around 23% by 2040, further intensifying pressure on health services.

Against this backdrop, All.Can Greece has published a landmark report titled “Mapping the Efficiency of Cancer Care in Greece”, based on the pilot implementation of the All.Can Action Guide for Efficient Cancer Care.

Rather than simply describing the current situation, the report aims to measure it — identifying where efficiency is lost across the cancer care pathway and where targeted reforms could make the greatest impact.

Cancer care efficiency in Greece: delays in care delivery

One of the most critical findings of the report relates to delays in the patient journey.

Despite the existence of modern infrastructure and highly specialized oncology centres, significant delays persist between initial suspicion, diagnosis, and the start of treatment.

These delays are not the result of a single bottleneck, but of systemic fragmentation:

  • fragmented referral pathways,
  • limited coordination between levels of care,
  • and the absence of standardized clinical protocols.

A key structural weakness is the lack of systematic monitoring of waiting times and time-to-treatment indicators. As a result, inefficiencies remain partially invisible to the system itself, limiting the ability to implement targeted improvements.

Fragmentation across the care continuum

The report highlights a broader issue of fragmentation in cancer care delivery.

The patient journey from primary care to specialist oncology services is often not clearly structured or consistently coordinated. Referral pathways depend heavily on individual practice rather than standardized national protocols.

A major gap is the absence of structured patient navigation services. In practice, this means that patients and families are often left to navigate a complex system on their own, increasing delays and adding unnecessary psychological burden.

At the same time, multidisciplinary tumor boards represent a positive development, supporting collaborative clinical decision-making across specialties. However, systematic monitoring of their performance remains limited.

The development of Comprehensive Cancer Centers is identified as a promising step forward, although further regulatory strengthening and clearer governance structures are still needed to maximize their impact.

Patient-centered care: progress with remaining gaps

Greece has made notable progress in collecting Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs), reflecting a growing commitment to integrating patient perspectives into care delivery.

However, patients’ access to their own clinical data remains limited, restricting their ability to actively participate in decision-making processes.

In addition, patient education and shared decision-making are not yet systematically embedded across the health system.

Another important gap concerns survivorship care. As cancer survival rates improve, the lack of structured long-term follow-up pathways leaves many patients without continuous support after active treatment ends.

Key policy directions

The report outlines several strategic priorities for improving cancer care efficiency in Greece:

  • Development of a comprehensive national cancer strategy with clear targets and governance mechanisms
  • Strengthening coordination across all levels of care
  • Implementation of standardized clinical pathways with defined time-to-treatment and quality indicators
  • Investment in oncology workforce capacity, particularly in shortage specialties
  • Establishment of structured patient navigation programmes
  • Acceleration of Comprehensive Cancer Center development
  • Systematic use of health data for monitoring performance and accountability
  • Greater patient engagement through PROMs, PREMs, and shared decision-making

Conclusion: a system with strong foundations but limited integration

Greece has many of the essential building blocks for a high-performing cancer care system — including infrastructure, clinical expertise, and emerging digital health capabilities.

However, the key challenge lies not in the existence of these components, but in their integration.

The All.Can Greece report highlights a system that is still operating in silos: strong individual elements that do not yet function as a fully connected care pathway.

In oncology, this lack of integration is not merely an organizational issue. It directly affects timeliness, patient experience, and ultimately outcomes.

The opportunity now lies in moving from fragmented capacity to coordinated care — where patients no longer have to bridge the gaps between system components themselves.

Source: Mapping-the-Efficiency-of-Cancer-Care-in-Greece-FINAL

Text/adaptation: Ifiyenia Anastasiou for Kapa3

EOPYY: New reimbursement framework for respiratory devices – What changes for patients

The reimbursement of respiratory devices under EOPYY has been updated through a new decision published in the Government Gazette (FEK) on April 27, 2026.

On April 27, 2026, a new EOPYY decision was published in the Government Gazette, establishing revised reimbursement prices for respiratory devices such as CPAP, Auto CPAP, and BiPAP machines.

These are medical devices primarily used by patients with respiratory disorders, including sleep apnoea, and they represent a fundamental part of daily treatment and quality of life.

EOPYY reimbursement for respiratory devices: what changes

With this regulation:

  • specific reimbursement prices are defined for each category of respiratory device
  • the prices apply to all products included in the Reimbursed Medical Devices Register
  • previous decisions for the same categories are replaced

Prices are unified per device category, regardless of manufacturer or commercial model.

What this means for patients

The new EOPYY reimbursement framework for respiratory devices provides a clearer structure for people living with respiratory conditions who depend on these devices in their daily lives:

  • it clarifies what is covered by EOPYY
  • it strengthens transparency regarding equipment costs
  • it ensures access to essential therapeutic tools that are not a choice, but a necessity

In some cases, a patient co-payment may apply when the device price exceeds the reimbursement amount.

Temporary nature of the regulation

The decision is considered temporary, as it is part of a transitional framework until the completion of the negotiation process for final pricing.

Nevertheless, it is fully applicable from the moment of its publication in the Government Gazette and constitutes the current reimbursement framework.

A more human perspective

Behind technical terms, codes, and regulatory tables, there are people who rely on these devices to breathe better, sleep better, and maintain a more stable daily life.

A clear reimbursement framework is not merely an administrative measure. It helps reduce uncertainty in situations that are already difficult to manage.

Source

The full text of the decision, along with the detailed list of reimbursed respiratory devices and corresponding prices, is available (in Greek) in the Government Gazette (FEK) of April 27, 2026.

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 in the First Half of March: Actions, Collaborations, and Updates for Oncology Patients

During the first half of March, Kapa3 continued to highlight important topics concerning the oncology patient support, rights, and daily lives  through initiatives, collaborations, and informational activities.

Efforts focused both on strengthening access to information and services, and on promoting practical and digital tools that make patients’ daily lives easier.

In an environment where patients’ needs remain complex and constantly evolving, reliable information, enhanced collaboration among stakeholders, and the promotion of holistic care are especially important.

Below is a summary of the main developments from the month.

Collaborations

Key partnerships were strengthened with the Sarcoma Fighters Patients Association, the Hellenic Federation of Persons with Multiple Sclerosis (HFoPwMS), and Doctor Homie, aiming to enhance information, support, and quality care for patients.

Actions & Presentations

Kapa3 participated in the scientific meeting “Cancer in 2026: Challenges and Breakthroughs,” emphasizing the pivotal role of supportive care for oncology patients, while also presenting recent developments addressing their evolving needs. Kapa3 also attented the event “Facing the Challenge of Artificial Intelligence” as we remain focused on supporting dialogue around the opportunities and challenges of A.I.

Patient Rights

Supporting oncology patients remains a central goal of our initiatives. Focus was given to updates on the 2026 constant attendance allowance and improved digital access for patients to their test results.

Digital Health & Research

A new European Commission report highlights the critical role of digital health technologies in transforming healthcare systems, outlining both opportunities and challenges for the future of care.

Awareness

March is Colorectal Cancer Awareness Month, reminding everyone of the importance of prevention and early detection.

Oncology patient support remains our top priority, and we continue to monitor developments — more news will follow.

Digital Access to Test Results: An Important Right for Patients

Digital access to medical test results has become an important right for patients in Greece, following new regulations that strengthen the use of the Digital Repository of Diagnostic Laboratory Results. According to the relevant decision published in the Government Gazette (March 2026), public and private healthcare units collaborating with EOPYY are required to record diagnostic test results in digital form within a specified timeframe.

This change is not just a technical procedure or an administrative obligation for healthcare providers. In practice, it represents a meaningful enhancement of patients’ rights, ensuring that every citizen can have immediate and organized access to their medical data.

Digital access to test results now reduces the need for physical documents, printed copies, or trips to diagnostic centers. Instead, results are stored in a unified digital environment connected to the Individual Electronic Health Record. This allows patients to have their test history consolidated, reducing the risk of losing important information.

For people living with cancer, this development is especially significant. Disease monitoring often involves repeated tests, visits to different doctors, and continuous evaluation of results. Immediate access to all data facilitates collaboration among healthcare professionals and contributes to more coordinated and effective care.

Moreover, the obligation to record results is linked to reimbursement procedures through EOPYY, enhancing transparency in the healthcare system. This ensures that only tests that have actually been performed are reimbursed, limiting abuse and strengthening the reliability of services.

It is also worth noting that data management is carried out under the current personal data protection framework, safeguarding patients’ privacy and information security.

Transitioning to a more digital healthcare system is not just a technological advancement. It is a step toward a more human, transparent, and accessible system of care, where the patient has an active role and meaningful control over their own data.

Ultimately, strengthening digital access to test results represents an important step forward in empowering patients and improving the quality of healthcare provided.

Source: Government Gazette, FEK B’ 1503/17.03.2026

Text/adaptation: Ifiyenia Anastasiou for Kapa3

New Collaboration between Cancer Guidance Center – Kapa3 and the Hellenic Federation of Persons with Multiple Sclerosis (HFoPwMS)

Cancer Guidance Center – Kapa3 announces its new collaboration with the Hellenic Federation of Persons with Multiple Sclerosis (HFoPwMS), strengthening synergies between organizations active in the field of health and patient support.

This collaboration aims to develop joint initiatives that will contribute to raising awareness, promoting public information, and providing meaningful support to people living with chronic conditions, with particular focus on cancer patients and persons living with Multiple Sclerosis. Through the exchange of knowledge, experience and good practices, the two organizations seek to strengthen actions that promote equal access to information, healthcare services and social inclusion for patients.

Cancer Guidance Center – Kapa3 is dedicated to supporting people living with cancer and their caregivers by providing reliable information, practical guidance and access to benefits and services. At the same time, the organization develops initiatives that enhance patients’ awareness of their rights and promote their psychosocial empowerment. Through initiatives such as Mobile Units, digital tools and educational programmes, Kapa3 promotes a patient-centred approach to cancer care, encouraging patients to actively participate in decisions concerning their health and quality of life, while fostering collaborations with organizations working in the fields of health and social support.

The Hellenic Federation of Persons with Multiple Sclerosis (HFoPwMS) is a secondary non-profit organization founded in 2008 with the aim of uniting and supporting primary associations of persons with Multiple Sclerosis across Greece, while also raising awareness about the disease among the wider public. The Federation currently brings together nine primary patient associations from across the country. HFoPwMS implements awareness and advocacy initiatives related to Multiple Sclerosis and works to ensure the equal participation of people with MS in the educational, professional, athletic and cultural life of the country. It is a member of the National Confederation of Disabled People (ESAmeA) and the European Multiple Sclerosis Platform (EMSP).

Within the framework of this collaboration, the two organizations plan to develop joint initiatives such as the organization of conferences, workshops and awareness events, the implementation of information and public awareness campaigns, participation in national and European programmes, as well as the development of joint research initiatives on issues related to patients’ quality of life. The partnership will also contribute to strengthening interdisciplinary cooperation and knowledge exchange among organizations active in the health sector.

This new collaboration reflects the shared vision of the two organizations to strengthen the voice of patients and promote a society that respects, supports and empowers people living with chronic conditions.

Vehicle Tax Exemption for People with Disabilities – Step-by-Step Guide

From February 4, 2026, citizens with disabilities can apply for a vehicle tax exemption for people with disabilities (PWD) through the new digital platform of AADE, without the need to submit physical documents. The process is simplified as the required data is automatically retrieved from KEPA of e-EFKA, making it easier for beneficiaries and their families. This digital solution allows fast and secure submission of requests while reducing bureaucracy.

How to apply for a vehicle tax exemption for PWD

1. Access the platform

  • Go to myAADE > Applications > Popular Applications > myCAR.

2. Who can submit the request

  • The beneficiary themselves, or

  • The parent/guardian for a minor, provided that the relationship is registered in the AADE Registry and the minor’s AMKA is included.

3. Vehicle selection

  • The system shows the eligible passenger cars. The beneficiary selects the vehicle for which they want the exemption.

4. Key points

  • Digitized Certificates of Disability (KEPA) issued from September 16, 2022, onwards can be used directly.

  • The exemption is valid from the start to the end of the certificate, including the years of issuance and expiration.

  • For certificates not digitized by e-EFKA, the request is submitted via the “My Requests” application on myAADE, attaching the required documents and selecting the competent tax office (DOY/KEFODE) for the beneficiary.

5. Information & support

  • By phone: 1521 (free of charge), weekdays 7:00–20:00

  • Online: my1521, 24/7, selecting Vehicle Topics > Exemptions > Requirements > Vehicle tax exemption due to disability

Kapa3 ensures that cancer patients and people with disabilities are informed about digital services that make their life easier, providing accurate and timely information about their rights.

You can find the AADE Press Release here.